Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 534-543

  Drinkut, Anja ^a,b,c   Tereshchenko, Yuliya ^a   Schulz, Jörg B ^a,c   Bähr, Mathias ^a   Kügler, Sebastian ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Department of Neurodegeneration and Restorative Research ^*  (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; NEURTURIN; OXIDOPAMINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL PROTECTION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HOST CELL; LOCOMOTION; MOUSE; NERVE PROJECTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; THERAPY EFFECT; TRANSGENE;

RATTUS;

EID: 84857782774     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.249     Document Type: Article

References (49)

1. Thomas, B and Beal, MF (2007). Parkinson's disease. Hum Mol Genet 16 (Spec No. 2): R183-R194.
2. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700. (Pubitemid 30396634)
3. Gash, DM, Zhang, Z, Ovadia, A, Cass, WA, Yi, A, Simmerman, L et al. (1996). Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255. (Pubitemid 26090648)
4. Eslamboli, A, Georgievska, B, Ridley, RM, Baker, HF, Muzyczka, N, Burger, C et al. (2005). Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25: 769-777. (Pubitemid 40170991)
5. Lang, AE, Gill, S, Patel, NK, Lozano, A, Nutt, JG, Penn, R et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466. (Pubitemid 43358066)
6. Marks, WJ Jr, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boulis, N et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9: 1164-1172.
7. Björklund, T and Kirik, D (2009). Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim Biophys Acta 1792: 703-713.
8. Manfredsson, FP, Okun, MS and Mandel, RJ (2009). Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 9: 375-388.
9. Bartus, RT, Herzog, CD, Chu, Y, Wilson, A, Brown, L, Siffert, J et al. (2011). Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 26: 27-36.
10. Kordower, JH, Palfi, S, Chen, EY, Ma, SY, Sendera, T, Cochran, EJ et al. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424. (Pubitemid 29416283)
11. Su, X, Kells, AP, Huang, EJ, Lee, HS, Hadaczek, P, Beyer, J et al. (2009). Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20: 1627-1640.
12. Manfredsson, FP, Tumer, N, Erdos, B, Landa, T, Broxson, CS, Sullivan, LF et al. (2009). Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17: 980-991.
13. Nakagawa, T and Schwartz, JP (2004). Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. Brain Pathol 14: 275-280. (Pubitemid 39095989)
14. Bresjanac, M and Antauer, G (2000). Reactive astrocytes of the quinolinic acidlesioned rat striatum express GFRalpha1 as well as GDNF in vivo. Exp Neurol 164: 53-59. (Pubitemid 30490722)
15. Mogi, M, Togari, A, Kondo, T, Mizuno, Y, Kogure, O, Kuno, S et al. (2001). Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci Lett 300: 179-181. (Pubitemid 32168216)
16. Leitner, ML, Molliver, DC, Osborne, PA, Vejsada, R, Golden, JP, Lampe, PA et al. (1999). Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci 19: 9322-9331. (Pubitemid 30228086)
17. Rind, HB and von Bartheld, CS (2002). Anterograde axonal transport of internalized GDNF in sensory and motor neurons. Neuroreport 13: 659-664. (Pubitemid 34293487)
18. Ciesielska, A, Mittermeyer, G, Hadaczek, P, Kells, AP, Forsayeth, J and Bankiewicz, KS (2011). Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 19: 922-927.
19. Douglas, R, Kellaway, L, Mintz, M and van Wageningen, G (1987). The crossed nigrostriatal projection decussates in the ventral tegmental decussation. Brain Res 418: 111-121. (Pubitemid 17155589)
20. Meredith, GE, Sonsalla, PK and Chesselet, MF (2008). Animal models of Parkinson's disease progression. Acta Neuropathol 115: 385-398.
21. Sajadi, A, Bauer, M, Thöny, B and Aebischer, P (2005). Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J Neurochem 93: 1482-1486. (Pubitemid 40853271)
22. Wang, L, Muramatsu, S, Lu, Y, Ikeguchi, K, Fujimoto, K, Okada, T et al. (2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9: 381-389. (Pubitemid 34414036)
23. Saavedra, A, Baltazar, G and Duarte, EP (2008). Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 86: 186-215.
24. Pascual, A, Hidalgo-Figueroa, M, Piruat, JI, Pintado, CO, Gómez-Díaz, R and López-Barneo, J (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11: 755-761. (Pubitemid 351896676)
25. Glazner, GW, Mu, X and Springer, JE (1998). Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system. J Comp Neurol 391: 42-49. (Pubitemid 28109618)
26. Sarabi, A, Hoffer, BJ, Olson, L and Morales, M (2003). Glial cell line neurotrophic factor-family receptor alpha-1 is present in central neurons with distinct phenotypes. Neuroscience 116: 261-273. (Pubitemid 36110451)
27. Sariola, H and Saarma, M (2003). Novel functions and signalling pathways for GDNF. J Cell Sci 116(Pt 19): 3855-3862. (Pubitemid 37279301)
28. Cao, JP, Yu, JK, Li, C, Sun, Y, Yuan, HH, Wang, HJ et al. (2008). Integrin beta1 is involved in the signaling of glial cell line-derived neurotrophic factor. J Comp Neurol 509: 203-210. (Pubitemid 351960784)
29. Guye, M, Bartolomei, F and Ranjeva, JP (2008). Imaging structural and functional connectivity: towards a unified definition of human brain organization? Curr Opin Neurol 21: 393-403.
30. Kaneda, K, Isa, K, Yanagawa, Y and Isa, T (2008). Nigral inhibition of GABAergic neurons in mouse superior colliculus. J Neurosci 28: 11071-11078.
31. Harting, JK, Updyke, BV and Van Lieshout, DP (2001). The visual-oculomotor striatum of the cat: functional relationship to the superior colliculus. Exp Brain Res 136: 138-142. (Pubitemid 32201997)
32. Huerta, MF, Van Lieshout, DP and Harting, JK (1991). Nigrotectal projections in the primate Galago crassicaudatus. Exp Brain Res 87: 389-401.
33. Tümer, N, Scarpace, PJ, Dogan, MD, Broxson, CS, Matheny, M, Yurek, DM et al. (2006). Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity. Neurobiol Aging 27: 459-470. (Pubitemid 43185332)
34. Nutt, JG, Burchiel, KJ, Comella, CL, Jankovic, J, Lang, AE, Laws, ER Jr et al. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73. (Pubitemid 36070646)
35. Aoi, M, Date, I, Tomita, S and Ohmoto, T (2000). The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 36: 319-325. (Pubitemid 30193352)
36. Miyoshi, Y, Zhang, Z, Ovadia, A, Lapchak, PA, Collins, F, Hilt, D et al. (1997). Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 42: 208-214. (Pubitemid 27340466)
37. Sandhu, JK, Gardaneh, M, Iwasiow, R, Lanthier, P, Gangaraju, S, Ribecco-Lutkiewicz, M et al. (2009). Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis 33: 405-414.
38. Pertusa, M, García-Matas, S, Mammeri, H, Adell, A, Rodrigo, T, Mallet, J et al. (2008). Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging 29: 1366-1379. (Pubitemid 351970594)
39. Do Thi, NA, Saillour, P, Ferrero, L, Dedieu, JF, Mallet, J and Paunio, T (2004). Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoterprevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther 11: 746-756. (Pubitemid 38659753)
40. Koerber, JT, Klimczak, R, Jang, JH, Dalkara, D, Flannery, JG and Schaffer, DV (2009). Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 17: 2088-2095.
41. Lawlor, PA, Bland, RJ, Mouravlev, A, Young, D and During, MJ (2009). Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17: 1692-1702.
42. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
43. Manfredsson, FP, Burger, C, Rising, AC, Zuobi-Hasona, K, Sullivan, LF, Lewin, AS et al. (2009). Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 17: 1857-1867.
44. Grimm, D, Zhou, S, Nakai, H, Thomas, CE, Storm, TA, Fuess, S et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102: 2412-2419. (Pubitemid 37193577)
45. Kügler, S, Meyn, L, Holzmüller, H, Gerhardt, E, Isenmann, S, Schulz, JB et al. (2001). Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol Cell Neurosci 17: 78-96. (Pubitemid 32113540)
46. Lee, Y, Messing, A, Su, M and Brenner, M (2008). GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56: 481-493.
47. Kowsky, S, Pöppelmeyer, C, Kramer, ER, Falkenburger, BH, Kruse, A, Klein, R et al. (2007). RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc Natl Acad Sci USA 104: 20049-20054.
48. Sauer, H and Oertel, WH (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415. (Pubitemid 24098798)
49. Eberhardt, O, Coelln, RV, Kugler, S, Lindenau, J, Rathke-Hartlieb, S, Gerhardt, E et al. (2000). Protection by synergistic effects of adenovirus-mediated X-chromosomelinked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. J Neurosci 20: 9126-9134. (Pubitemid 32042915)